Dr. Glenn Begley is a bio-technology advisor and former head of cancer research at drugmaker Amgen.

格伦·贝格利博士是生物技术顾问，也是制药商安进公司癌症研究部门的前负责人。

America's Federal Trade Commission filed a lawsuit to block the $28bn takeover of Horizon Therapeutics by Amgen.

美国联邦贸易委员会提起诉讼，阻止安进(Amgen)以280亿美元收购Horizon Therapeutics。

That changed on May 17, when the Food and Drug Administration approved Aimovig, a drug from Amgen and Novartis.

好在5月17日，情况有了好转，因为这天，美国食品和药物管理局批准了安进和诺华两家公司合作研发的Aimovig。

Also, drug maker Amgen is planning to build a $365 million biomanufacturing plant not far from the Intel factory.

此外，制药公司安进计划在距离英特尔工厂不远的地方建造一座价值3。65亿美元的生物制药厂。

Biotech heavyweight Amgen plans to buy Horizon Therapeutics for $28bn.

生物科技巨头安进计划以 280 亿美元收购 Horizo​​n Therapeutics。

Have Amgen and Horizon responded or have others in the industry responded?

Amgen 和 Horizo​​n 是否做出了回应，或者业内其他人是否做出了回应？

So Amgen said that it was disappointed with this decision, that it remains committed to completing this deal.

所以安进表示对这一决定感到失望，它仍然致力于完成这笔交易。

Ten years ago, he and other scientists at Amgen reported even lower rates of confirmation when they tried to repeat published cancer experiments.

十年前，他和安进公司的其他科学家报告称，当他们试图重复已发表的癌症实验时，证实率更低。

Do you have any idea how hard it is to develop a new drug if you're not Pfizer, or Amgen, or Merck?

如果不是辉瑞 阿目金或者默克这类大制药公司你知道普通公司要开发新药有多难吗？